New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
07:12 EDTMYGN, TSROMyriad Genetics announces HRD collaboration with TESARO
Myriad Genetics (MYGN) announced that Tesaro (TSRO) will use Myriad's novel HRD, or homologous recombination deficiency, test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase, or PARP, inhibitor, niraparib, currently in Phase 3 clinical development. Specific terms of the deal were not disclosed.
News For MYGN;TSRO From The Last 14 Days
Check below for free stories on MYGN;TSRO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
16:02 EDTTSROTESARO files to sell $165M of convertible senior notes due 2021
Subscribe for More Information
September 10, 2014
09:20 EDTTSROTESARO management to meet with Leerink
Subscribe for More Information
September 9, 2014
07:11 EDTMYGNMyriad Genetics presented results from myPath Melanoma test clinical study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use